Retatrutide
Research Overview · Mechanism of Action · Reconstitution Guide
Overview
Retatrutide (LY3437943) is a synthetic 36-amino acid peptide developed by Eli Lilly that functions as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors — making it the first triple incretin receptor agonist to enter clinical trials. This tri-agonist approach targets three distinct but complementary metabolic pathways simultaneously, producing additive effects on energy expenditure, appetite suppression, and hepatic glucose output that exceed what dual or single agonists can achieve. Phase II trial data published in 2023 demonstrated mean body weight reductions of up to 24.2% at 48 weeks, the largest weight loss reported for any pharmacological agent in a clinical trial at the time.
Mechanism of Action
Retatrutide's three-receptor mechanism works through distinct but synergistic pathways. GLP-1 receptor agonism activates Gs-coupled adenylyl cyclase in pancreatic beta cells, potentiating glucose-dependent insulin secretion, suppressing glucagon from alpha cells, slowing gastric emptying, and activating hypothalamic POMC/CART satiety circuits while suppressing NPY/AgRP orexigenic neurons. GIP receptor agonism enhances insulin secretion in a glucose-dependent manner, modulates adipocyte lipid metabolism, and acts centrally to reduce food intake — with evidence suggesting GIP receptor activation potentiates GLP-1R signaling through receptor cross-talk. Glucagon receptor agonism is the key differentiator from dual agonists: it dramatically increases energy expenditure through thermogenesis in brown adipose tissue and hepatic fatty acid oxidation. In isolation, glucagon receptor agonism would be hyperglycemic; co-administered with GLP-1R agonism, the insulin-stimulating effects counterbalance glucagon's glycemic impact while retaining its thermogenic and lipolytic benefits. The net result is a compound that simultaneously reduces caloric intake (GLP-1 + GIP), increases caloric expenditure (glucagon), and improves insulin sensitivity (GLP-1 + GIP) — three independent mechanisms acting in concert.
Key Studies & References
Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 389:514–526. Key finding: 24.2% mean body weight reduction at highest dose (12 mg) at 48 weeks; 100% of participants achieved ≥5% weight loss.
Coskun T et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34:1234–1247. Preclinical characterization and Phase I data.
Nahra R et al. (2021). Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes. Diabetes Care 44:1433–1442. Contextual dual GLP-1/glucagon agonist data for mechanistic comparison.
Bacteriostatic Water Reconstitution Guide
Research Use Only — The following reconstitution information is provided for in vitro laboratory research purposes only. Not for human or veterinary use.
Recommended Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Standard Volume
Add 2 mL bacteriostatic water to a 5 mg vial to yield a 2.5 mg/mL (2500 mcg/mL) solution.
Working Concentration
2.5 mg/mL standard. For lower-dose research protocols, dilute further with bacteriostatic water or sterile saline.
Storage (Reconstituted)
Reconstituted: 2–8°C, use within 28 days. Lyophilized: -20°C, desiccated, protected from light.
Stability Window
Stable for 28 days at 2–8°C post-reconstitution. Discard if solution becomes cloudy, discolored, or particulate matter is visible. Avoid repeated freeze-thaw cycles of reconstituted solution.
Technique
Inject bacteriostatic water slowly down the side of the vial wall. Do not inject directly onto the lyophilized cake. Gently swirl — do not shake or vortex. Allow 2–3 minutes for complete dissolution. Solution should be clear and colorless to pale yellow.
Notes
Retatrutide contains a fatty acid modification for albumin binding (similar to semaglutide). The benzyl alcohol preservative in bacteriostatic water is essential for multi-use vials — sterile water limits shelf life to 24–48 hours and is not recommended for extended research protocols.
Research Dosing Reference
The following dosing information is derived from published Phase II clinical trial data and preclinical research literature and is provided for reference purposes only. It does not constitute medical advice.
Clinical / Human Research Range
Phase II trial (NEJM 2023): 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous weekly. Dose escalation over 16 weeks from a 0.5 mg starting dose. Maximum studied dose: 12 mg/week.
Preclinical Models
Rodent studies: 0.1–3 mg/kg subcutaneous, weekly. Diet-induced obesity (DIO) mouse models used in foundational characterization studies.
Calculation Example
For a 2.5 mg/mL solution: a 4 mg research dose = 1.6 mL. A 1 mg dose = 0.4 mL. Use a 2 mL syringe for doses above 1 mg.